Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 3/20 | 0.46 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480452 | 0.90 | BRAF (0.45) | BRAFMAPK14KDRCNR1 | |
| SCHEMBL12227088 | 0.83 | SMN1; SMN2 (0.48) | EPHB4KDRCNR1 | |
| SCHEMBL2476671 | 0.83 | BRAF (0.55) | BRAFBLMMAPK14RAF1EPHB4 | |
| SCHEMBL2478417 | 0.82 | BRAF (0.56) | BRAFBLMMAPK14RAF1EPHB4 | |
| SCHEMBL12227091 | 0.74 | BRAF (0.39) | BRAFMAPK14RAF1PIK3CA | |
| SCHEMBL1850249 | 0.74 | BRAF (0.59) | BRAFBLMMAPK14RAF1EPHB4 | |
| SCHEMBL1977410 | 0.73 | MAPK14 (0.64) | BRAFBLMMAPK14RAF1EPHB4 | |
| SCHEMBL1847951 | 0.73 | BRAF (0.64) | BRAFBLMMAPK14EPHB4KDR | |
| SCHEMBL2475882 | 0.72 | BRAF (0.45) | BRAFMAPK14KDRCNR1 | |
| SCHEMBL1847148 | 0.72 | BRAF (0.75) | BRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| EP-2373664-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K19, MAP4K3, MAP3K15 | BRAF 41/4885BLM 2985/4885MAPK14 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.